News

Dunsire Joins Xtuit to Fight Microenvironment

News

Press Release

XTuit Pharmaceuticals Appoints Dr. Deborah Dunsire as President and Chief Executive Officer

Industry Leader and Oncology Innovator to Lead Company’s Growth and Strategy for Novel Microenvironment-Targeted Drugs in Fibrotic Diseases and Immuno-Oncology

News

Xtuit goes ‘micro’ in cancer, fibrosis with $22M series A

News

XTuit Gets $22M From NEA, Polaris to Battle Cancer, Liver Disease

Call it ground zero in a patient’s battle with cancer: the tumor microenvironment, the tissue around a cancerous cell that gets tricked into doing its bidding. That critical terrain is becoming the focus of a lot of fresh ideas for scientists—and one of them is taking shape today, with the emergence of a startup called XTuit Pharmaceuticals.

News

NEA, Polaris Bet $22M on Startup, Xtuit, to Break Down Tumor Microenvironment

Logic would say cancer drugs can’t work if something is keeping them out of the tumor. The latest startup from the Bob Langer/Polaris Partners factory floor just got $22 million to clear out some of the barriers around tumors, and make it easier for some of the exciting new immuno-oncology drugs to do what they do best.

News

NEA joins Polaris in backing XTuit's cancer/fibrosis pipeline with $22M A round

After spending the last four years germinating an idea for a new biotech company with some top scientists, the partners at Polaris have allied with New Enterprise Associates and a trio of biotech investors to launch XTuit, jumping out of stealth mode with a $22 million A round and a new take on fighting cancer and liver disease.